GSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions
GSK plc (NYSE:GSK) has decided to terminate the License and Collaboration Agreement with Lyell Immunopharma Inc (NASDAQ:LYEL). The termination is effective on December…
Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock
HC Wainwright initiated coverage of Lyell Immunopharma Inc (NASDAQ:LYEL) with a Buy rating and a price target of $12 per share. Lyell…
Lyell Immunopharma Announces FDA Clearance Of Its IND For LYL845, A TIL Product Candidate Enhanced With Its Novel Epigenetic Reprogramming Technology For Solid Tumors
Autologous TIL therapy enhanced with Lyell's Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved function
Phase 1 trial
Why U.S. Stocks Are Trading Lower; AZZ Earnings And More
U.S. stocks traded lower this morning as investors digested the recent jobs report for the month of June.
89 Biggest Movers From Friday
Gainers
Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.